Search results
...Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating...
WFRV 5 Green Bay· 6 days agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA® ...
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance...
Benzinga· 7 days agoFindings from the extended LIBERTY studies and associated post-hoc analysis support the long-term efficacy and safety of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab[1],[2]Data from a
Female City Worker: My Encounter With Derek Chauvin Left Me ‘Traumatized’
The Daily Beast via Yahoo News· 6 days agoPatricia DayKiller cop Derek Chauvin is facing new allegations that he used excessive force,...
Expel Marjorie Taylor Greene
The Dispatch via Yahoo News· 14 hours agoOh, we get it. We do. It is as plain as day: Moscow Madge is still looking for some flimsy post-hoc vindication for her risible, failed attempt to get...
Losing Muscle with GLP-1 RAs? There May be a Drug for That
Medscape· 4 days agoMedications in development would preserve muscle mass and augment fat loss when used in combination...
Does Daytime Hypoglycemia Contribute to Impaired Awareness?
Medscape· 7 days agoIn older adults with T1D, less daytime hypoglycemia was the biggest predictor of improvements in IAH...
Anti-Epilepsy Drug Improves Sleep Apnea Symptoms in Mid-Stage Trial
MedPage Today· 6 days agoThe anti-epilepsy drug sulthiame significantly improved symptoms of moderate-to-severe obstructive...
Hochschild Mining (LON:HOC) Hits New 52-Week High at $177.20
ETF DAILY NEWS· 6 days agoHochschild Mining plc (LON:HOC – Get Free Report) reached a new 52-week high on Monday . The company...
Avadel to present new data on LUMRYZ at SLEEP 2024 conference By Investing.com
Investing.com· 5 days agoAvadel Pharmaceuticals plc (NASDAQ: NASDAQ:AVDL), a biopharmaceutical company, announced its...
Tezepelumab Shows Potential for COPD, Negative Trial Notwithstanding
MedPage Today· 6 days agoAsthma drug may benefit patients with blood eosinophil counts indicative of type 2 inflammation